))
Harnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
Manage episode 414417595 series 3381434
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 0.25
Valid until: 20-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/harnessing-the-nafldnash-epidemic-preparing-for-a-new-treatment-paradigm/15673/
Managed care pharmacists play a key role in driving treatment through primary care providers, who are often charged with making pivotal treatment distinctions for patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This Chairman’s Perspective highlights the key takeaways from the live symposium that took place at the 2023 AMCP meeting. Dr. Younossi takes us through the morbidity and mortality associated with advanced fibrosis, compares the known costs of not treating advanced fibrosis with the estimated costs of treating NASH, and takes a deeper dive into the identification of patients who meet the likely indications for treatments of NASH with new liver-directed therapy.=
…
continue reading
Valid until: 20-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/harnessing-the-nafldnash-epidemic-preparing-for-a-new-treatment-paradigm/15673/
Managed care pharmacists play a key role in driving treatment through primary care providers, who are often charged with making pivotal treatment distinctions for patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This Chairman’s Perspective highlights the key takeaways from the live symposium that took place at the 2023 AMCP meeting. Dr. Younossi takes us through the morbidity and mortality associated with advanced fibrosis, compares the known costs of not treating advanced fibrosis with the estimated costs of treating NASH, and takes a deeper dive into the identification of patients who meet the likely indications for treatments of NASH with new liver-directed therapy.=
598 episoder
Del
